文献速递消化系统肿瘤

靶向GUCY2C的CAR-T细胞治疗转移性结直肠癌的I期研究

Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.
PubMed 文献 · J Clin Oncol · 2026-06-04

这项开放标签、单中心I期研究评估了靶向GUCY2C的CAR-T细胞在转移性结直肠癌三线及以上治疗中的安全性和疗效。剂量递增阶段未观察到剂量限制性毒性,选择DL3进行扩展研究;20例患者中仅1例(5.0%)出现3级细胞因子释放综合征和神经毒性,3级腹泻发生率为55.0%。19例可评估患者的客观缓解率为26.3%,DL3组10例患者ORR为40.0%、中位无进展生存期为7.0个月,GUCY2C中高表达者ORR达50.0%、mPFS为9.0个月。

要点

  • GUCY2C CAR-T在经治转移性结直肠癌中安全性可接受,3级CRS和神经毒性发生率低。
  • DL3组客观缓解率达40.0%,中位无进展生存期7.0个月。
  • 疗效与CAR-T剂量水平相关,GUCY2C中高表达者缓解率更高。

核心结论

  • GUCY2C CAR-T在第三线或更后线转移性结直肠癌患者中显示出可接受的安全性和较高的缓解率,临床疗效与CAR-T剂量水平相关。

研究设计与样本

  • 开放标签、单中心I期研究,包括3+3剂量递增阶段和剂量扩展研究。
  • 剂量递增阶段测试四个剂量水平:3×10^8(DL1)、6×10^8(DL2)、12×10^8(DL3)和20×10^8(DL4)CAR-T细胞。
  • 主要终点为首次输注后28天内的安全性和耐受性;肿瘤组织经组织学确认GUCY2C表达阳性。
  • 共20例转移性结直肠癌患者在接受淋巴细胞清除后输注GUCY2C CAR-T细胞。

主要发现

  • 剂量递增阶段未观察到剂量限制性毒性,选择DL3进行剂量扩展研究。
  • 20例患者中仅1例(5.0%)出现3级细胞因子释放综合征和神经毒性;3级腹泻发生于11例患者(55.0%)。
  • 19例可评估患者的客观缓解率(ORR)为26.3%,所有缓解患者均在DL3和DL4组。
  • DL3组10例患者ORR为40.0%,中位无进展生存期(mPFS)为7.0个月。
  • DL3组中GUCY2C中高表达患者的ORR达50.0%,mPFS为9.0个月。

临床怎么用

  • 对于三线及以上转移性结直肠癌患者,GUCY2C CAR-T可能是一种具有可接受安全性和较高缓解率的选择。
  • 治疗前应确认肿瘤组织GUCY2C表达阳性,并关注腹泻等不良反应的管理。
  • 剂量水平可能影响疗效,DL3(12×10^8)与DL4(20×10^8)组观察到缓解。

局限性

  • 本研究为开放标签、单中心I期研究,样本量有限。
  • 剂量扩展研究仅纳入20例患者,疗效和安全性需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The clinical efficacies of third- or later-line therapies for metastatic colorectal cancer (CRC) are extremely limited. The purpose of this study was to evaluate the safety and efficacy of a chimeric antigen receptor T (CAR T) cell targeting guanylyl cyclase 2C (GUCY2C) that was steadily expressed in all stages of CRC in a phase I study. PATIENTS AND METHODS: This was an open-label, single-center, phase I study, consisting of a 3 + 3 pattern dose-escalation phase and a dose-expansion investigation. Tumor tissues were histologically confirmed positive for GUCY2C expression. Four dose levels were tested in the dose-escalation phase, including 3 × 108 (DL1), 6 × 108 (DL2), 12 × 108 (DL3), and 20 × 108 (DL4) CAR T cells. The primary end points were safety and tolerability within 28 days after the first infusion. RESULTS: In the dose-escalation phase, dose-limiting toxicity was not observed. DL3 was chosen for dose-expansion study. A total of 20 patients with metastatic CRC were infused with GUCY2C CAR T after lymphodepletion, and only one patient (5.0%) showed grade 3 cytokine release syndrome and neurotoxicity. Grade 3 diarrhea occurred in 11 patients (55.0%). Of 19 evaluable patients, the objective response rate (ORR) was 26.3%, with all responding patients in DL3 and DL4 groups. Of 10 patients in the DL3 group, the ORR was 40.0% and the median progression-free survival time (mPFS) was 7.0 months. Among patients showing medium-to-high GUCY2C expression in the DL3 group, the ORR achieved 50.0% and the mPFS was 9.0 months. CONCLUSION: GUCY2C CAR T showed acceptable safety profile and high response rate in patients with third- or later-line CRC, and the clinical efficacy was associated with CAR T dose level.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Qi C, Liu C, Gong J, et al. Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2026. PMID: 42241671. doi:10.1200/JCO-25-01090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。